We've merged Palleos Healthcare to form a wide-reaching European CRO.
Find out more
OCT Clinical has successfully initiated patient recruitment for the clinical trial in a Ph3 lung cancer study. This is a randomized open-label trial, the aim of which is to determine the efficacy and safety of a test drug in combination with chemotherapy and platinum as first-line therapy in patients with metastatic non-squamous cell non-small cell lung cancer. The Sponsor of the study is a US-based immuno-oncology biotech company.
The recruitment target for the entire global study is 560 patients in four countries in Eastern Europe. The site initiation in Ukraine, Georgia, and Belarus is planned for January 2022. Participants will be treated until the disease progresses or intolerance to therapy develops. The duration of the project is almost 4 years, until the end of 2024.
Within this project, the OCT Clinical team is responsible for a wide scope of clinical trial services: study feasibility analysis and site selection, clinical trial approval and regulatory support, logistics, medical monitoring, project management, and site management and monitoring.
OCT Clinical is now operating under Palleos Healthcare brand name.
“The merger will undoubtedly create significant synergies, not just doubling but squaring the expertise of both companies”, Philip Räth, Ph.D., managing director at Palleos, said in the release.
“OCT Clinical is proud to join forces with palleos healthcare, as it has an excellent reputation in the industry it serves. Now we can offer tailored solutions to our clients to meet their diverse clinical research needs and accelerate the time of bringing their products to market”, Dmitry Sharov, CEO at OCT Clinical.
